Could a cheaper shingles booster offer same protection?
NCT ID NCT07753265
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial tests whether a single dose of a live-attenuated shingles vaccine can effectively boost immunity in adults aged 50 and older who have already received the recombinant shingles vaccine. The study measures antibody and cellular immune responses after the booster. If it works, it might provide a more affordable or convenient option for maintaining shingles protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- live-attenuated zoster vaccine
- What this could lead to
- If successful, this could offer a more accessible or cost-effective booster option for shingles prevention in older adults.
- What could go wrong
- This is an early-phase trial with only 100 participants, so results may not be conclusive. The live vaccine carries a small risk of causing shingles-like symptoms, especially in those with weakened immunity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPSE ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.